ResearcherAzienda Ospedaliero-Universitaria CareggiActive in the last 2 years
Serena Pillozzi
Matched on ORCID iD 0000-0001-8861-8718; OpenAlex author ID A5090870392. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 4
- The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 20… Co-author DOI 10.1186/s13045-026-01834-2↗
- Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. Last author DOI 10.3389/fonc.2025.1613773↗
- KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients. Co-author DOI 10.3389/fonc.2023.1295936↗
- Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lorenzo Antonuzzo · 4 shared papers, 2021–2026 · strength 0.83
- Paper The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emergi… DOI 10.1186/s13045-026-01834-2↗
- Paper Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. DOI 10.3389/fonc.2025.1613773↗
- Paper KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic ade… DOI 10.3389/fonc.2023.1295936↗
- Daniele Lavacchi · 3 shared papers, 2023–2026 · strength 0.72
- Paper The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emergi… DOI 10.1186/s13045-026-01834-2↗
- Paper Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. DOI 10.3389/fonc.2025.1613773↗
- Paper KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic ade… DOI 10.3389/fonc.2023.1295936↗
- Andrea Galli · 3 shared papers, 2023–2026 · strength 0.72
- Paper The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emergi… DOI 10.1186/s13045-026-01834-2↗
- Paper Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. DOI 10.3389/fonc.2025.1613773↗
- Paper KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic ade… DOI 10.3389/fonc.2023.1295936↗
- Elisa Giommoni · 2 shared papers, 2021–2026 · strength 0.43
- Paper The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emergi… DOI 10.1186/s13045-026-01834-2↗
- Paper Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Stu… DOI 10.3390/curroncol28030164↗
- Simone Polvani · 2 shared papers, 2023–2025 · strength 0.40
- Paper Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration. DOI 10.3389/fonc.2025.1613773↗
- Paper KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic ade… DOI 10.3389/fonc.2023.1295936↗
- Giuseppe Defazio · 1 shared paper, 2025 · strength 0.24
- Vanja Vaccaro · 1 shared paper, 2021 · strength 0.11
- Caterina Vivaldi · 1 shared paper, 2021 · strength 0.11
- Francesco Di Costanzo · 1 shared paper, 2021 · strength 0.11
- Guido Giordano · 1 shared paper, 2021 · strength 0.11
- Evaristo Maiello · 1 shared paper, 2021 · strength 0.11
- Giampaolo Tortora · 1 shared paper, 2021 · strength 0.11
- Tiziana Pia Latiano · 1 shared paper, 2021 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.